This suggests that CNS cancers with IDH1/ATRX deficiency are not subject to the same DNA lesions or repair processes as other CNS cancers and they may potentially belong to a separate patient subclass, though we could not identify evidence of this. Here, ATRX is linked to central nervous system cancer.